NewLink Genetics Corp (NLNK)

0.07 1.10
NASDAQ : Health Care
Prev Close 6.50
Open 6.51
Day Low/High 6.42 / 6.62
52 Wk Low/High 9.23 / 56.16
Volume 287.13K
Avg Volume 784.50K
Exchange NASDAQ
Shares Outstanding 29.42M
Market Cap 186.82M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting NLNK Put And Call Options For August 18th

Investors in NewLink Genetics Corp saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NLNK options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Biotech Movers: NewLink, Inovio, Juno

Biotech Movers: NewLink, Inovio, Juno

NewLink Genetics, Inovio Pharmaceuticals and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

NewLink Genetics To Regain Rights To GDC-0919

Management to Host Conference Call Thursday, June 8 at 8:30 am ET

Notable Wednesday Option Activity: NLNK, WTW, GEF

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in NewLink Genetics Corp , where a total of 2,935 contracts have traded so far, representing approximately 293,500 underlying shares. That amounts to about 47.5% of NLNK's average daily trading volume over the past month of 617,940 shares.

Commit To Buy NewLink Genetics Corp At $10, Earn 23.3% Annualized Using Options

Investors considering a purchase of NewLink Genetics Corp shares, but tentative about paying the going market price of $11.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $10 strike, which has a bid at the time of this writing of $1.45.

Biotech Movers: Loxo, NewLink, BioCryst

Biotech Movers: Loxo, NewLink, BioCryst

Loxo Oncology, NewLink Genetics and BioCryst Pharmaceuticals were among the biotech movers in premarket trading on Monday.

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Relative Strength Alert For NewLink Genetics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Newman Ferrara LLP Announces Corporate Governance Investigation Of NewLink Genetics Corporation - NLNK

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ:NLNK) into potential breaches of fiduciary duty...

NewLink Genetics Reports First Quarter 2017 Financial Results And Updates Clinical Trial Guidance

Management to Host Conference Call Today at 8:30 a.m. ET

Six Stocks Spiking Up With Huge Volume

Six Stocks Spiking Up With Huge Volume

Here's a technical look at how to play six stocks trending higher with strong volume.

NEWLINK GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In NewLink Genetics Corporation (NLNK) To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQGM:NLNK).

Interim Phase 2 Data Demonstrate Robust Response Rate With Indoximod In Combination With Keytruda® (pembrolizumab) For Patients With Advanced Melanoma At AACR Plenary

59% Objective Response Rate (ORR) and 80% Disease Control Rate (DCR) in 51 Patients with Non-ocular Melanoma

Strange: Bullish NLNK Analysts Actually See -7.33% Downside

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with NewLink Genetics Corp . The average 12-month price target for NLNK — averaging the work of 6 analysts — reveals an average price target of $22.33/share.

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.

NLNK Crosses Above Average Analyst Target

In recent trading, shares of NewLink Genetics Corp have crossed above the average analyst 12-month target price of $18.17, changing hands for $19.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.